Gefitinib ('Iressa', ZD1839) in advanced non-small-cell lung cancer patients progressed to chemotherapy

被引：0
|
作者：
Cortes-Funes, H
Figueiras, MC
Martín-Algarra, S
Salinas, P
Massutí, B
Gascón, P
Rosell, R
机构：
[1] Hosp Univ 12 Octubre, Madrid, Spain
[2] Hosp Pontevedra, Pontevedra, Spain
[3] Univ Navarra Clin, Navarra, Spain
[4] MD Anderson Int Canc Ctr, Madrid, Spain
[5] Gen Hosp, Alicante, Spain
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] Hosp Germans Trias & Pujol, Barcelona, Spain
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] A case of diffuse interstitial pneumonitis in a patient with stage IV non-small-cell lung cancer receiving gefitinib ('Iressa', ZD1839) treatment
    Gervais, R
    Chasles, J
    Rivière, A
    Michels, JJ
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S29
  • [42] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
    H S Parra
    R Cavina
    F Latteri
    P A Zucali
    E Campagnoli
    E Morenghi
    G C Grimaldi
    M Roncalli
    A Santoro
    [J]. British Journal of Cancer, 2004, 91 : 208 - 212
  • [43] Gefitinib ('Iressa', ZD1839) as third-line therapy for a patient with symptomatic brain metastases from non-small-cell lung cancer
    Azémar, M
    Stoll, C
    Unger, C
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S25 - S25
  • [44] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Latteri, F
    Zucali, PA
    Campagnoli, E
    Morenghi, E
    Grimaldi, GC
    Roncalli, M
    Santoro, A
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 208 - 212
  • [45] ZD1839 (Iressa™):: For more than just non-small cell lung cancer
    Ranson, M
    [J]. ONCOLOGIST, 2002, 7 : 16 - 24
  • [46] Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells
    Satoh, H
    Ishikawa, H
    Nakayama, M
    Fujiwara, M
    Ohtsuka, M
    Sekizawa, K
    [J]. ONCOLOGY REPORTS, 2004, 12 (03) : 615 - 619
  • [47] Clinically meaningful response to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [48] Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
    Xin-Lin Mu
    Long-Yun Li
    Xiao-Tong Zhang
    Shu-Lan Wang
    Meng-Zhao Wang
    [J]. BMC Cancer, 4
  • [49] Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
    Mu, XL
    Li, LY
    Zhang, XT
    Wang, SL
    Wang, MZ
    [J]. BMC CANCER, 2004, 4 (1)
  • [50] Disease stabilisation following gefitinib ('Iressa', ZD1839) therapy in a patient with metastatic non-small-cell lung cancer and very poor performance status
    Vincent, MD
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S34 - S35
12345